Protagonist Hopes For ‘Paradigm Change’ With Polycythemia Drug But Needs Phase III Safety Data
Could Free Patients From Blood-Taking And Cardiovascular Risks
Executive Summary
The company’s late-breaker data suggests it is on the path to success in polycythemia vera, but cancer fears must be addressed with ongoing longer-term study.